EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Serum ferritin as a tumor marker in patients with squamous cell carcinoma of the head and neck



Serum ferritin as a tumor marker in patients with squamous cell carcinoma of the head and neck



Cancer 57(2): 305-311



A double antibody enzyme immunoassay was used to measure serum ferritin levels in several different control and tumor-bearing populations collected from 2 institutions. The control groups consisted of normal volunteers, smokers, and Latter Day Saints. No statistically significant differences were noted in ferritin levels between pairs of these groups. Differences were noted among the normal groups when separated on the basis of age and sex, the higher ferritin levels in individuals older than 32 years of age and in men. By one-way analysis of variance, most control groups and subgroups were shown to have significantly lower levels (P < 0.05) than the head and neck cancer group, with the exception of male smokers, who had levels comparable to male head and neck cancer patients. Serum ferritin levels were higher in head and neck cancer patients than in controls; however, there was no difference when compared with patients with other types of solid malignancies or when considering the anatomic site of the head and neck lesion. Ferritin levels were significantly (P < 0.05) higher in patients with advanced (Stages III and IV) cancer than in those individuals with Stage I or II cancer. In patients with no evidence of clinical disease 5 years after treatment, the ferritin level had essentially returned to normal. In a group of head and neck cancer patients followed longitudinally, a significant decline in ferritin levels (P < 0.05) was seen by 5 months after the completion of successful treatment. Furthermore, ferritin levels showed a tendency to increase or remain at high levels in patients with a poor prognosis and to decrease in those patients with a favorable prognosis, giving support to the contention that ferritin may prove to be a valuable tumor marker in head and neck cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 006401105

Download citation: RISBibTeXText

PMID: 3942962

DOI: 10.1002/1097-0142(19860115)57:2<305::aid-cncr2820570219>3.0.co;2-d



Related references

Ferritin: A potential serum marker for lymph node metastasis in head and neck squamous cell carcinoma. Oncology Letters 17(1): 314-322, 2019

Serum ferritin as a tumor marker for patients with carcinoma of the head and neck. Proceedings of the American Association for Cancer Research & American Society of Clinical Oncology 21: 233, 1980

The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck. Anticancer Research 22(5): 3093-3097, 2003

Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncology 43(10): 1021-1025, 2007

Shift in IgG subclasses A tissue non specific tumor marker in patients with squamous cell carcinoma of the head and neck. British Journal of Cancer 77(SUPPL 1): 45, 1998

Study of new tumor marker, CYFRA 211, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Journal Of Nuclear Medicine. 37(5 Suppl.): 145p, 1996

Relevance of the new tumor marker SCC (squamous cell carcinoma antigen) for the diagnosis and follow-up control of squamous epithelial carcinoma of the head and neck. Hno 37(11): 454-459, 1989

The scc antigen a new tumor marker for squamous cell carcinoma in the head and neck. Archives of Oto-Rhino-Laryngology 246(6): 458, 1989

Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years. Clinical Oral Investigations 20(8): 2097-2104, 2016

Current clinical relevance of squamous cell carcinoma antigen as a new tumor marker in patients with head and neck cancer results of a prospective study after 24 months. Archives of Oto-Rhino-Laryngology 246(6): 458, 1989

Scc antigen a new tumor marker for squamous cell carcinoma in the head and neck area. Hno 37(11): 454-459, 1989

Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Annals of Otology, Rhinology, and Laryngology 114(10): 768-776, 2005

Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Archives of Otolaryngology--Head & Neck Surgery 121(2): 177-181, 1995

Squamous cell carcinoma antigen as tumor marker for head and neck malignancy. Kawasaki Medical Journal 13(1): 19-24, 1987

Squamous cell carcinoma antigen present clinical relevance of a new tumor marker in patients with head and neck cancer preliminary results of a prospective study after 12 months. Laryngologie Rhinologie Otologie 67(8): 420-425, 1988